Diabetes Fundamentals Series 2026: Class 1 – Getting to the Nitty Gritty

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/23

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering the pathophysiology, epidemiology, diagnostic criteria, classification schemes, and clinical management strategies discussed in Class 1 of the Diabetes Fundamentals Series 2026.

24 Terms

1
New cards

Social Drivers of Health (SDOH)

The economic, environmental, political, and social conditions in which individuals live that are largely beyond direct personal control and account for significant disparities in clinical outcomes and health inequality.

2
New cards

Person-Centered Care

An approach to healthcare that considers an individual's comorbidities and prognoses, respects individual preferences, needs, and values, and ensures that the person's values guide all clinical decision-making.

3
New cards

ADCES7 Self-Care Behaviors™

A framework identifying seven essential self-care behaviors for successful diabetes management: healthy eating, being active, monitoring, taking medication, problem solving, reducing risks, and healthy coping.

<p>A framework identifying seven essential self-care behaviors for successful diabetes management: healthy eating, being active, monitoring, taking medication, problem solving, reducing risks, and healthy coping.</p>
4
New cards

Pancreatic Beta Cells

Endocrine cells comprising approximately 60%60\% of pancreatic islets that produce and secrete insulin and amylin to lower blood glucose levels.

5
New cards

Pancreatic Alpha Cells

Endocrine cells comprising approximately 30%30\% of pancreatic islets responsible for secreting glucagon, which elevates circulating blood glucose.

6
New cards

Pancreatic Delta Cells

Endocrine cells comprising approximately 10%10\% of pancreatic islets that secrete somatostatin.

7
New cards

Incretins

Gut hormones, including GLP-1 and GIP, released by L cells of the intestinal mucosa that stimulate beta-cell insulin secretion and lower glucose in response to food intake.

8
New cards

Diabetes Prevention Program (DPP) Lifestyle Intervention

A structured 16-session core curriculum completed within 6 months6\,\text{months} (followed by 6 months6\,\text{months} of maintenance) aimed at achieving at least 7%7\% weight loss and 150 minutes150\,\text{minutes} of moderate-intensity physical activity per week, proven to reduce type 2 diabetes risk by 58%58\% over 3 years3\,\text{years}.

9
New cards

Prediabetes Diagnostic Criteria

Glycemic ranges indicating elevated diabetes risk: Fasting Plasma Glucose of 100–125 mg/dL100\text{--}125\,\text{mg/dL}, 2-hour plasma glucose during a 75-g75\text{-g} OGTT of 140–199 mg/dL140\text{--}199\,\text{mg/dL}, or an A1C of 5.7–6.4%5.7\text{--}6.4\%.

10
New cards

Diabetes Mellitus Diagnostic Criteria

Standard thresholds for diagnosing diabetes: Fasting Plasma Glucose ≥126 mg/dL\ge 126\,\text{mg/dL}, 2-hour OGTT glucose ≥200 mg/dL\ge 200\,\text{mg/dL}, random plasma glucose ≥200 mg/dL\ge 200\,\text{mg/dL} with classic symptoms of hyperglycemia, or an A1C ≥6.5%\ge 6.5\%.

11
New cards

Estimated Average Glucose (eAG)

A clinical calculation translating an A1C percentage into average glucose units using the formula eAG=28.7×A1C−46.7\text{eAG} = 28.7 \times \text{A1C} - 46.7, where each 1%1\% increase in A1C represents approximately 29 mg/dL29\,\text{mg/dL} in blood glucose.

12
New cards

Type 1 Diabetes Mellitus

An autoimmune form of diabetes accounting for 5–10%5\text{--}10\% of cases, characterized by immune-mediated pancreatic beta-cell destruction, insulin sensitivity requiring 0.5–1.0 units/kg/day0.5\text{--}1.0\,\text{units/kg/day} of exogenous insulin, and a peak onset typically between ages 10–14 years10\text{--}14\,\text{years}.

13
New cards

Islet Autoantibodies

Serum antibodies directed against beta-cell components used to diagnose or predict type 1 diabetes, primarily including glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8), and insulin autoantibodies.

14
New cards

Stage 1 Type 1 Diabetes

The presymptomatic phase of type 1 diabetes defined by the presence of two or more islet autoantibodies with normoglycemia.

15
New cards

Stage 2 Type 1 Diabetes

The presymptomatic phase of type 1 diabetes defined by the presence of multiple islet autoantibodies accompanied by dysglycemia (FPG 100–125 mg/dL100\text{--}125\,\text{mg/dL}, 2-h PG 140–199 mg/dL140\text{--}199\,\text{mg/dL}, or A1C 5.7–6.4%5.7\text{--}6.4\%).

16
New cards

Stage 3 Type 1 Diabetes

The clinical phase of type 1 diabetes marked by overt hyperglycemia and symptoms that meet standard diagnostic criteria.

17
New cards

Teplizumab (Tzield)

An anti-CD3 monoclonal antibody administered as a 14-day14\text{-day} intravenous infusion that delays the progression from stage 2 to clinical stage 3 type 1 diabetes (median delay of 48.4 months48.4\,\text{months} vs. 24.4 months24.4\,\text{months} for placebo) in eligible individuals aged ≥8 years\ge 8\,\text{years}.

18
New cards
<p>Acanthosis Nigricans</p>

Acanthosis Nigricans

A cutaneous marker of hyperinsulinemia and insulin resistance presenting as velvety, hyperpigmented plaques in skin folds such as the neck, axillae, groin, knuckles, and elbows.

19
New cards

The Noxious Nine

The multi-organ pathophysiological defects driving type 2 diabetes: decreased beta-cell insulin secretion, increased alpha-cell glucagon secretion, elevated hepatic glucose production, increased lipolysis, decreased muscle glucose uptake, neurotransmitter dysfunction, increased renal glucose reabsorption, decreased incretin effect, and hypercortisolism.

20
New cards

Type 3c Diabetes (Pancreatogenic Diabetes)

A form of diabetes accounting for 5–10%5\text{--}10\% of cases, characterized by structural and functional loss of insulin secretion secondary to exocrine pancreatic dysfunction (most frequently caused by chronic or acute pancreatitis in  70%~70\% of cases, pancreatectomy, trauma, neoplasia, or cystic fibrosis).

<p>A form of diabetes accounting for $$5\text{--}10\%$$ of cases, characterized by structural and functional loss of insulin secretion secondary to exocrine pancreatic dysfunction (most frequently caused by chronic or acute pancreatitis in $$~70\%$$ of cases, pancreatectomy, trauma, neoplasia, or cystic fibrosis).</p>
21
New cards

Gestational Diabetes Mellitus (GDM)

Glucose intolerance first identified during pregnancy, typically screened for between 24–28 weeks24\text{--}28\,\text{weeks} of gestation, which confers a 50%50\% risk of developing type 2 diabetes within 5 years5\,\text{years} postpartum.

22
New cards

One-Step Strategy for GDM (IADPSG Consensus)

A diagnostic protocol using a fasting 75-g75\text{-g} OGTT with plasma glucose evaluated after at least an 8-hour8\text{-hour} overnight fast; diagnosis is confirmed if fasting ≥92 mg/dL\ge 92\,\text{mg/dL}, 1-hour ≥180 mg/dL\ge 180\,\text{mg/dL}, or 2-hour ≥153 mg/dL\ge 153\,\text{mg/dL}.

23
New cards

Two-Step Strategy for GDM (NIH Consensus)

A screening approach beginning with a non-fasting 50-g50\text{-g} oral glucose load (Step 1); if the 1-hour plasma glucose is ≥130–140 mg/dL\ge 130\text{--}140\,\text{mg/dL}, a diagnostic fasting 100-g100\text{-g} 3-hour OGTT (Step 2) is performed, requiring at least 22 of 44 thresholds to be met or exceeded (95,180,155,140 mg/dL95, 180, 155, 140\,\text{mg/dL}).

24
New cards

Empowerment Approach

A diabetes education philosophy founded on helping individuals recognize and cultivate their internal capacity to take responsibility for their own lives and diabetes self-management decisions.